Samer A. Srour

2.2k total citations
98 papers, 682 citations indexed

About

Samer A. Srour is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Samer A. Srour has authored 98 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 48 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Samer A. Srour's work include CAR-T cell therapy research (30 papers), Hematopoietic Stem Cell Transplantation (24 papers) and Acute Myeloid Leukemia Research (20 papers). Samer A. Srour is often cited by papers focused on CAR-T cell therapy research (30 papers), Hematopoietic Stem Cell Transplantation (24 papers) and Acute Myeloid Leukemia Research (20 papers). Samer A. Srour collaborates with scholars based in United States, Israel and Thailand. Samer A. Srour's co-authors include Richard E. Champlin, Partow Kebriaei, Elizabeth J. Shpall, Gabriela Rondón, Stefan O. Ciurea, Qaiser Bashir, Uday Popat, Katayoun Rezvani, Julianne Chen and Chitra Hosing and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Samer A. Srour

92 papers receiving 669 citations

Peers

Samer A. Srour
Zhengming Jin China
Leyla Shune United States
Zhen‐Huan Hu United States
Vladan Vučinić Germany
Jenna D. Goldberg United States
Sumithira Vasu United States
Kathleen Dorritie United States
Christoph Scheid Germany
Kerstin Schäfer‐Eckart Germany
Linghui Xia China
Zhengming Jin China
Samer A. Srour
Citations per year, relative to Samer A. Srour Samer A. Srour (= 1×) peers Zhengming Jin

Countries citing papers authored by Samer A. Srour

Since Specialization
Citations

This map shows the geographic impact of Samer A. Srour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samer A. Srour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samer A. Srour more than expected).

Fields of papers citing papers by Samer A. Srour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samer A. Srour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samer A. Srour. The network helps show where Samer A. Srour may publish in the future.

Co-authorship network of co-authors of Samer A. Srour

This figure shows the co-authorship network connecting the top 25 collaborators of Samer A. Srour. A scholar is included among the top collaborators of Samer A. Srour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samer A. Srour. Samer A. Srour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nieto, Yago, Jeremy Ramdial, Benigno C. Valdez, et al.. (2025). Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research. 31(6). 975–982. 1 indexed citations
2.
Ramdial, Jeremy, Laura Di Clemente, Pinaki P. Banerjee, et al.. (2024). Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies. Blood. 144(Supplement 1). 4841–4841.
3.
Pal, Sumanta K., Melissa A. Reimers, Benjamin Garmezy, et al.. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2676–TPS2676. 4 indexed citations
4.
Ciurea, Stefan O., Uday Popat, Jeremy Ramdial, et al.. (2024). Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Advances. 8(12). 3237–3245. 2 indexed citations
5.
Srour, Samer A., Jeremy Pantin, Sagar S. Patel, et al.. (2024). AML-521 Treatment of Acute Myeloid Leukemia With Orca-T. Clinical Lymphoma Myeloma & Leukemia. 24. S317–S317. 1 indexed citations
6.
Abedi, Mehrdad, Samer A. Srour, Amandeep Salhotra, et al.. (2024). Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies. Blood. 144(Supplement 1). 382–382. 3 indexed citations
7.
Joseph, Jacinth, Samer A. Srour, Denái R. Milton, et al.. (2023). Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and Cellular Therapy. 29(12). 770.e1–770.e6. 3 indexed citations
8.
9.
Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2023). Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 29(12). 757–762. 8 indexed citations
10.
Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2022). Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 28(11). 752.e1–752.e6. 4 indexed citations
11.
Srour, Samer A. & Serkan Akın. (2022). Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. SHILAP Revista de lepidopterología. 6(1). 19–30. 12 indexed citations
12.
Ciurea, Stefan O., Jolie Schafer, Piyanuch Kongtim, et al.. (2021). Results of a Phase I Study with Mb-IL21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Refractory Acute Myeloid Leukemia. Transplantation and Cellular Therapy. 27(3). S77–S78. 1 indexed citations
13.
Saliba, Rima M., Uri Greenbaum, Qing Ma, et al.. (2021). Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Advances. 5(17). 3407–3417. 5 indexed citations
14.
Shah, Mithun Vinod, Rima M. Saliba, Ankur Varma, et al.. (2021). Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. British Journal of Haematology. 193(5). 1004–1008. 8 indexed citations
15.
Lee, Hans C., Krina K. Patel, Sheeba K. Thomas, et al.. (2020). Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 20(5). e221–e238. 9 indexed citations
16.
Lin, Paul, Rima M. Saliba, Uday Popat, et al.. (2019). Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation. 25(5). 1039–1044. 10 indexed citations
17.
Ciurea, Stefan O., Piyanuch Kongtim, Ankur Varma, et al.. (2019). Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood. 135(6). 449–452. 28 indexed citations
18.
Kongtim, Piyanuch, Omar Hasan, Ankur Varma, et al.. (2019). Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(1). 197–203. 15 indexed citations
19.
Wu, Evan & Samer A. Srour. (2017). Paraneoplastic Hyperleukocytosis in Pancreatic Adenocarcinoma. 3(1). 84–86. 1 indexed citations
20.
Wu, Evan & Samer A. Srour. (2017). Paraneoplastic Hyperleukocytosis in Pancreatic Adenocarcinoma. SHILAP Revista de lepidopterología. 3(1). 84–86. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengming Jin Breakdown of academic impact, for papers by Leyla Shune Breakdown of academic impact, for papers by Zhen‐Huan Hu Breakdown of academic impact, for papers by Vladan Vučinić Breakdown of academic impact, for papers by Jenna D. Goldberg Breakdown of academic impact, for papers by Sumithira Vasu Breakdown of academic impact, for papers by Kathleen Dorritie Breakdown of academic impact, for papers by Christoph Scheid Breakdown of academic impact, for papers by Kerstin Schäfer‐Eckart Breakdown of academic impact, for papers by Linghui Xia
Rankless by CCL
2026